Sclerostin inhibition: A novel therapeutic approach in the treatment of osteoporosis

International Journal of Women's Health

Volumn 7, Issue , 2015, Pages 565-580

  Shah, Arti D ^a   Shoback, Dolores ^a,b   Michael Lewiecki, E ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

Anabolic therapies; Osteoporosis; Romosozumab; Sclerostin; Wnt signaling

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BLOSOZUMAB; BONE MORPHOGENETIC PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PLACEBO; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; ROMOSOZUMAB; SCLEROSTIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTHRALGIA; BACKACHE; BONE DENSITY; BONE FRAGILITY; BONE MASS; BONE METABOLISM; BONE MINERALIZATION; BONE STRENGTH; BONE TURNOVER; CONSTIPATION; COUGHING; DISEASE MODEL; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERANCE; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; GENE; HEADACHE; HEPATITIS; HOT FLUSH; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; LOSS OF FUNCTION MUTATION; LRP5 GENE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SOST GENE; TREATMENT RESPONSE;

EID: 84930939206     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S73244     Document Type: Review

References (66)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diag­nosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785–795.
2. Costa AG, Bilezikian JP, Lewiecki EM. Update on romosozumab: a humanized monoclonal antibody to sclerostin. Expert Opin Biol Ther. 2014;14(5):697–707.
3. International Osteoporosis Foundation [homepage on the Internet]. Osteoporosis facts and statistics. International Osteoporosis Founda­tion Bone Health. Available from: http://www.iofbonehealth.org/facts-statistics. Accessed February 11, 2015.
4. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465–475.
5. Kanis JA on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary healthcare level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK; 2007. Available from: http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf. Accessed February 11, 2015.
6. Wade SW, Strader C, Fitzpatrick LA, Anthony MS, O’Malley CD. Estimating prevalence of osteoporosis: Examples from industrialized countries. Arch Osteoporos. 2014;9(1):182.
7. National Osteoporosis Foundation [homepage on the Internet]. What women need to know. Available from: http://nof.org/articles/235. Accessed February 11, 2015.
8. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726–1733.
9. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: Now and the future. Lancet. 2011;377(9773):1276–1287.
10. Martin TJ. Bone biology and anabolic therapies for bone: Current status and future prospects. J Bone Metab. 2014;21(1):8–20.
11. Tella SH, Gallagher JC. Biological agents in management of osteopo­rosis. Eur J Clin Pharmacol. 2014;70(11):1291–1301.
12. Bernabei R, Martone AM, Ortolani E, Landi F, Marzetti E. Screening, diagnosis and treatment of osteoporosis: A brief review. Clin Cases Miner Bone Metab. 2014;11(3):201–207.
13. Augustine M, Horwitz MJ. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis. Curr Osteoporos Rep. 2013;11(4):400–406.
14. Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a thera­peutic target for bone diseases. Expert Opin Ther Targets. 2009;13(4):485–496.
15. Veverka V, Henry AJ, Slocombe PM, et al. Characterization of the structural features and interactions of sclerostin: Molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem. 2009;284(16):10890–10900.
16. Burgers TA, Williams BO. Regulation of Wnt/beta-catenin signaling within and from osteocytes. Bone. 2013;54(2):244–249.
17. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: From human mutations to treatments. Nat Med. 2013;19(2):179–192.
18. Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148(6):2635–2643.
19. Baron R, Rawadi G. Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep. 2007;5(2):73–80.
20. Ai M, Heeger S, Bartels CF, Schelling DK; Osteoporosis-Pseudoglioma Collaborative Group. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am J Hum Genet. 2005;77(5):741–753.
21. Kedlaya R, Veera S, Horan DJ, et al. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome. Sci Transl Med. 2013;5(211):211ra158.
22. Keupp K, Beleggia F, Kayserili H, et al. Mutations in WNT1 cause differ­ent forms of bone fragility. Am J Hum Genet. 2013;92(4):565–574.
23. van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007;22(1):19–28.
24. van Dinther M, Zhang J, Weidauer SE, et al. Anti-sclerostin antibody inhibits internalization of sclerostin and sclerostin-mediated antagonism of Wnt/LRP6 signaling. PLoS One. 2013;8(4):e62295.
25. Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19(13):1842–1844.
26. Atkins GJ, Rowe PS, Lim HP, et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res. 2011;26(7):1425–1436.
27. Balemans W, Ebeling M, Patel N, et al. Increased bone density in scle­rosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537–543.
28. Van Hul W, Balemans W, Van Hul E, et al. Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21. Am J Hum Genet. 1998;62(2):391–399.
29. van Lierop AH, Hamdy NA, van Egmond ME, Bakker E, Dikkers FG, Papapoulos SE. Van Buchem disease: Clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res. 2013;28(4):848–854.
30. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia scle­rosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577–589.
31. Staehling-Hampton K, Proll S, Paeper BW, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002;110(2):144–152.
32. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39(2):91–97.
33. Wergedal JE, Veskovic K, Hellan M, et al. Patients with van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of iner­tia than normal. J Clin Endocrinol Metab. 2003;88(12):5778–5783.
34. van Lierop AH, Hamdy NA, Hamersma H, et al. Patients with scleros­teosis and disease carriers: Human models of the effect of sclerostin on bone turnover. J Bone Miner Res. 2011;26(12):2804–2811.
35. Gardner JC, van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab. 2005;90(12):6392–6395.
36. Costa AG, Bilezikian JP. Sclerostin: Therapeutic horizons based upon its actions. Curr Osteoporos Rep. 2012;10(1):64–72.
37. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23(6):860–869.
38. Niziolek PJ, Farmer TL, Cui Y, Turner CH, Warman ML, Robling AG. High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes. Bone. 2011;49(5):1010–1019.
39. Lin C, Jiang X, Dai Z, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res. 2009;24(10):1651–1661.
40. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003;22(23):6267–6276.
41. Tu X, Rhee Y, Condon KW, et al. SOST downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 2012;50(1):209–217.
42. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treat­ment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578–588.
43. Ominsky MS, Niu QT, Li C, Li X, Ke HZ. Tissue-level mecha­nisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J Bone Miner Res. 2014;29(6):1424–1430.
44. Stolina M, Dwyer D, Niu QT, et al. Temporal changes in systemic and local expression of bone turnover markers during six months of scle­rostin antibody administration to ovariectomized rats. Bone. 2014;67:305–313.
45. Li X, Niu QT, Warmington KS, et al. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. Endocrinology. 2014;155(12):4785–4797.
46. Li X, Ominsky MS, Warmington KS, et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreat­ment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology. 2011;152(9):3312–3322.
47. Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by mono­clonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010;25(12):2647–2656.
48. Ominsky MS, Li C, Li X, et al. Inhibition of sclerostin by mono­clonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011;26(5):1012–1021.
49. Yao Q, Ni J, Hou Y, Ding L, Zhang L, Jiang H. Expression of sclerostin scFv and the effect of sclerostin scFv on healing of osteoporotic femur fracture in rats. Cell Biochem Biophys. 2014;69(2):229–235.
50. Alaee F, Virk MS, Tang H, et al. Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model. J Orthop Res. 2014;32(2):197–203.
51. Virk MS, Alaee F, Tang H, Ominsky MS, Ke HZ, Lieberman JR. Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J Bone Joint Surg Am. 2013;95(8):694–701.
52. Agholme F, Isaksson H, Li X, Ke HZ, Aspenberg P. Anti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in rats. Acta Orthop. 2011;82(5):628–632.
53. Tian X, Setterberg RB, Li X, Paszty C, Ke HZ, Jee WS. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone. 2010;47(3):529–533.
54. Ross RD, Edwards LH, Acerbo AS, et al. Bone matrix quality after scle­rostin antibody treatment. J Bone Miner Res. 2014;29(7):1597–1607.
55. Spatz JM, Ellman R, Cloutier AM, et al. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res. 2013;28(4):865–874.
56. Cui L, Cheng H, Song C, et al. Time-dependent effects of sclerostin antibody on a mouse fracture healing model. J Musculoskelet Neuronal Interact. 2013;13(2):178–184.
57. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin anti­body in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25(5):948–959.
58. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19–26.
59. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmeno­pausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–420.
60. Becker CB. Sclerostin inhibition for osteoporosis –a new approach. N Engl J Med. 2014;370(5):476–477.
61. ClinicalTrials.gov [homepage on the Internet]. Romosozumab. Clini­calTrials.gov A service of the US National Institutes of Health. Avail­able from: http://clinicaltrials.gov/ct2/results?term=romosozumab&Search=Search. Accessed February 11, 2015.
62. McColm J, Hu L, Womack T, Tang CC, Chiang AY. Single- and multiple-dose randomized studies of blosozumab, a monoclonal anti­body against sclerostin, in healthy postmenopausal women. J Bone Miner Res. 2014;29(4):935–943.
63. Recker R, Benson C, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in post­menopausal women with low bone mineral density. J Bone Miner Res. 2015;30(2):216–224.
64. Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: A decade of experience. J Bone Miner Res. 2012;27(12):2419–2428.
65. Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years. J Bone Miner Res. 2012;27(12):2429–2437.
66. Balemans W, Van Den Ende J, Freire Paes-Alves A, et al. Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21. Am J Hum Genet. 1999;64(6):1661–1669.